TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31234691

Group type: EXPERIMENTAL
Intervention: C+C (cyclopentolate 1% + cyclopentolate 1%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+T (cyclopentolate 1% + tropicamide 1%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atropine 0.5% (after C+C)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atropine 0.5% (after C+T)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+C (dark pigmentation)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+T (dark pigmentation)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atropine (dark pigmentation, crying)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+C (dark pigmentation, crying)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+T (dark pigmentation, crying)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atropine (medium pigmentation, crying)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+C (medium pigmentation, crying)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C+T (medium pigmentation, crying)
Number of subjects: 67
Study: 29071764

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 24
Study: 25881320

Group type: EXPERIMENTAL
Intervention: Bravecto™ (fluralaner), 25 mg/kg body weight, single oral administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Advocate® (imidacloprid/moxidectin), 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight, topical administration on three occasions at 28-day intervals
Number of subjects: 16
Study: 23741066

Group type: EXPERIMENTAL
Intervention: Quisinostat (JNJ-26481585) administered orally, once daily in three weekly cycles, with doses ranging from 2-12 mg for continuous dosing and 6-19 mg for intermittent dosing schedules.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedules (four days on/three days off; every Monday, Wednesday, Friday; every Monday and Thursday)
Number of subjects: 92
Study: 21162697

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Open-label titration phase (Tapentadol ER)
Number of subjects: 588
Study: 18971855

Group type: EXPERIMENTAL
Intervention: Topical 0.05% ciclosporin A (CsA) for 3 months after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard topical therapy)
Number of subjects: 60
Study: 17052283

Group type: EXPERIMENTAL
Intervention: Maternal health factors (hypertensive disorders)
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Maternal health factors (antepartum haemorrhage)
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Maternal health factors (higher haemoglobin levels)
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Overall perinatal mortality rate
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Overall stillbirth rate
Number of subjects: 1584
Study: 12941721

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 units subcutaneous injection once daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (physiological saline equivalent volume once daily)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 11019420

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMS) 60 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMS) added to selected antianginal drugs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol, Verapamil, Isosorbide dinitrate, Nifedipine
Number of subjects: 29
Study: 8618579

Group type: EXPERIMENTAL
Intervention: Aerosolized synthetic surfactant (13.5 mg of dipalmitoylphosphatidylcholine per milliliter) administered continuously for up to five days
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo (0.45 percent saline) administered continuously for up to five days
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Aerosolized synthetic surfactant
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo (0.45 percent saline)
Number of subjects: 725
Study: 1570391

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30

Group type: COMPARATOR
Intervention: No patches
Number of subjects: 30
Study: 6089249

Group type: EXPERIMENTAL
Intervention: Diazepam (0.28 mg/kg)
Number of subjects: 0
Study: 30609409

Group type: EXPERIMENTAL
Intervention: Newborn genomic sequencing (nGS)
Number of subjects: 159
Study: 30016151

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (10 1-min cycling intervals at 95% peak workload, 3 times per week for 11 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Endurance Training (40-min cycling at 50% peak workload, 3 times per week for 11 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 16
Study: 26749219

Group type: EXPERIMENTAL
Intervention: HYD 30 mg once daily
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: HYD 20 to 120 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: HYD 120 mg once daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: HYD 30 mg
Number of subjects: 410
Study: 25069991

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (o‐CEE), 0.45 mg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (t‐E2), 50 mcg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo for 48 months
Number of subjects: 727
Study: 23179383

Group type: COMPARATOR
Intervention: D + 3 progesterone treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: D + 4 progesterone treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Morula/blastocyst stage embryos
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cleavage stage embryos
Number of subjects: 88

Group type: COMPARATOR
Intervention: Mixed stage transfers
Number of subjects: 88
Study: 19732051

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5, 5, 10, 20 mg)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1058
Study: 18044196

Group type: EXPERIMENTAL
Intervention: Exposure therapy combined with other Cognitive‐Behavioral Therapy (CBT) components
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 16563281

Group type: EXPERIMENTAL
Intervention: Acute Myocardial Infarction (AMI) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Unstable Angina (UA) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stable Angina (SA) group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 12392861

Group type: EXPERIMENTAL
Intervention: Palm handheld computers for patient diaries
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electronic reminders for protocol compliance
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional paper-based patient diaries
Number of subjects: 12
Study: 11331450

Group type: EXPERIMENTAL
Intervention: GH/GLN
Number of subjects: 16

Group type: COMPARATOR
Intervention: GLN
Number of subjects: 16
Study: 9489976

Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil once daily for 2 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil once daily for 2 additional weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 8157711

Group type: EXPERIMENTAL
Intervention: Nal‐Glu plus T plus Teslac
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nal‐Glu plus T
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 3
Study: 3358810

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care (T group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular outpatient clinic care (NT group)
Number of subjects: 59
Study: 31883845

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg (n = 46)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg (n = 41)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Brodalumab vs Ustekinumab (anti-IL-23/IL-12)
Number of subjects: 116
Study: 30208344

Group type: EXPERIMENTAL
Intervention: Physical Health Nurse Consultant (PHNC) in addition to usual care
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 28012190

Group type: EXPERIMENTAL
Intervention: Scalpel debridement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Salicylic acid patches (Callívoro Marthand®)
Number of subjects: 62
Study: 26172283

Group type: EXPERIMENTAL
Intervention: FRC FPDs made with pre-impregnated glass or polyethylene fibre materials
Number of subjects: 120
Study: 23329886

Group type: COMPARATOR
Intervention: Group C (tidal volume 8 ml/kg, frequency 12/min)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group L (tidal volume 6 ml/kg, frequency 16/min)
Number of subjects: 50
Study: 21262922

Group type: EXPERIMENTAL
Intervention: Computer-based order intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative antibacterials (treatment indication)
Number of subjects: 0
Study: 18199726

Group type: EXPERIMENTAL
Intervention: Buccal mucosa cells (BMC) harvested at baseline and 3 days after baseline.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Leukocytes collected in heparin and EDTA.
Number of subjects: 31
Study: 16600934

Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g . kg(‐1) . d(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Amino acid mixture (0.8 g . kg(‐1) . d(‐1))
Number of subjects: 26
Study: 15000437

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Glyburide and Metformin
Number of subjects: 20
Study: 11345687

Group type: EXPERIMENTAL
Intervention: Ketoprofen lysinate solution (160 mg in 100 ml, twice a day for seven days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Benzidamine hydrochloride (15 ml, twice a day for seven days)
Number of subjects: 120
Study: 8773944

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 1729854

Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pimobendan 10 mg daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30537550

Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Continuous TKI with chemotherapy (nontransplant arm)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Achieving complete remission (CR) at induction end
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Achieving major molecular response (MMR) at 3 months
Number of subjects: 68
Study: 29898217

Group type: EXPERIMENTAL
Intervention: Topical ozenoxacin cream 1%
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 411
Study: 27028282

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study: 24557105

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) of 30 N
Number of subjects: 79

Group type: COMPARATOR
Intervention: No cricoid pressure (CP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 79
Study: 22150098

Group type: EXPERIMENTAL
Intervention: Red wine (8 ounces daily for 1 month)
Number of subjects: 36

Group type: COMPARATOR
Intervention: White wine (8 ounces daily for 1 month)
Number of subjects: 36
Study: 20886510

Group type: EXPERIMENTAL
Intervention: CoQ(10) treatment (1200 mg/day for 60 days)
Number of subjects: 30
Study: 17302514

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous iron sucrose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n=5) without iron treatment
Number of subjects: 10
Study: 15598664

Group type: EXPERIMENTAL
Intervention: Motivational interviewing techniques during interactive group-based orientation sessions
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control condition (not explicitly detailed)
Number of subjects: 162
Study: 11864795

Group type: EXPERIMENTAL
Intervention: Coaching intervention (n = 121)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Usual medical care (n = 124)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 245
Study: 10435727

Group type: EXPERIMENTAL
Intervention: Busulphan at 600 mg/m2 with cyclophosphamide alone (Group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Busulphan at 16 mg/kg with cyclophosphamide and ATG (Group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Busulphan at 600 mg/m2 (Group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Busulphan at 16 mg/kg (Group A)
Number of subjects: 23
Study: 8574032

Group type: EXPERIMENTAL
Intervention: Gd zeolite oral suspension (250 to 1500 mL; 6 to 60 micrograms of Gd+3/mL) administered before and after MRI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gd zeolite oral suspension
Number of subjects: 30
Study: 2278526

Group type: EXPERIMENTAL
Intervention: 1% ephedrine hydrochloride nasal douche
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study: 7428408

Group type: EXPERIMENTAL
Intervention: 30 mg mianserin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 60 mg mianserin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release amitriptyline
Number of subjects: 47
Study: 30776522

Group type: EXPERIMENTAL
Intervention: CM‐OIT
Number of subjects: 41
Study: 27862021

Group type: EXPERIMENTAL
Intervention: Objectifying task (manual/computer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-objectifying task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 0
Study: 26387891

Group type: EXPERIMENTAL
Intervention: LBNP (‐40 mmHg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mental stress (serial subtraction)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: COMBO (LBNP+mental stress)
Number of subjects: 18
Study: 24488838

Group type: EXPERIMENTAL
Intervention: AN-EXRP
Number of subjects: 32

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 32
Study: 22753648

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19827484

Group type: EXPERIMENTAL
Intervention: Topically applied hydrogel containing 0.5% morphine plus subcutaneous placebo infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo gel plus subcutaneous infusion of 5mg morphine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo gel plus subcutaneous placebo infusion
Number of subjects: 9
Study: 17201543

Group type: EXPERIMENTAL
Intervention: Leaders high in SDO partnered with an agreeable follower (confederate)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Followers high in RWA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High SDO leader - high RWA follower dyads
Number of subjects: 4

Group type: COMPARATOR
Intervention: Leaders low in SDO
Number of subjects: 4

Group type: COMPARATOR
Intervention: Followers low in RWA
Number of subjects: 4
Study: 15451907

Group type: EXPERIMENTAL
Intervention: Diabetes and no heart failure (group 2, n = 107)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: No diabetes and heart failure (group 3, n = 247)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Heart failure history with no diabetes (group 5, n = 41)
Number of subjects: 922

Group type: COMPARATOR
Intervention: No diabetes and no heart failure (group 1, n = 324)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Diabetes and heart failure (group 4, n = 183)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Heart failure history with diabetes (group 6, n = 20)
Number of subjects: 922
Study: 11528307

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 84
Study: 9626795

Group type: EXPERIMENTAL
Intervention: Carboplatin (600 mg/m2) and Cyclophosphamide (1,500 mg/m2) with filgrastim
Number of subjects: 27

Group type: COMPARATOR
Intervention: Carboplatin (300 mg/m2) and Cyclophosphamide (600 mg/m2) without filgrastim
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide at 2.5 times standard dose with filgrastim
Number of subjects: 27

Group type: COMPARATOR
Intervention: Carboplatin and Cyclophosphamide at standard dose without filgrastim
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide at 2.5 times standard dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide after first cycle
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide after fourth cycle
Number of subjects: 27
Study: 8055283

Group type: EXPERIMENTAL
Intervention: Conventional brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic brachytherapy with radiolabeled antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 0
Study: 3126626

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30772342

Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (50 mg) + Sublingual isosorbide dinitrate (5 mg)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Diclofenac suppositories (50 mg)
Number of subjects: 886
Study: 28224713

Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss (IBWL)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (community campaign alone)
Number of subjects: 136
Study: 25801162

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.3 mg/kg) with midazolam (0.02 mg/kg) and fentanyl (1 μg/kg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Midazolam (0.02 mg/kg) and fentanyl (1 μg/kg) with placebo (0.9% sodium chloride)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups (K and C)
Number of subjects: 97
Study: 23686563

Group type: EXPERIMENTAL
Intervention: 50 mg/day elemental iron supplements
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50 mg/day elemental iron + 500 mg/day ascorbic acid
Number of subjects: 60
Study: 22080318

Group type: EXPERIMENTAL
Intervention: Low fat chocolate milk (1 g carbohydrate per kg body weight)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low fat chocolate milk
Number of subjects: 13

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte beverage (CE)
Number of subjects: 13
Study: 19109447

Group type: EXPERIMENTAL
Intervention: Lokomat robotic-assisted gait training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 63
Study: 17407641

Group type: EXPERIMENTAL
Intervention: 1 g paracetamol plus 130 mg caffeine
Number of subjects: 320

Group type: COMPARATOR
Intervention: 1 g paracetamol alone
Number of subjects: 320

Group type: COMPARATOR
Intervention: 130 mg caffeine alone
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 15893088

Group type: EXPERIMENTAL
Intervention: <HS degree
Number of subjects: 0

Group type: COMPARATOR
Intervention: At least a college degree
Number of subjects: 0
Study: 12369656

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study: 9647338

Group type: EXPERIMENTAL
Intervention: tolrestat (200 mg a day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study: 8090462

Group type: EXPERIMENTAL
Intervention: FASTPAC threshold strategy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Standard threshold strategy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Suprathreshold screening strategy
Number of subjects: 135
Study: 2582720

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at a rate of 2 i.u./h for 1 h, followed by 4 i.u./h for a further hour
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 14
Study: 1101845

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 23
Study: 31872791

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study: 29843627

Group type: EXPERIMENTAL
Intervention: Placenta praevia/accreta
Number of subjects: 20017

Group type: EXPERIMENTAL
Intervention: Caesarean section
Number of subjects: 20017

Group type: EXPERIMENTAL
Intervention: Mothers in Asia
Number of subjects: 20017
Study: 28011260

Group type: EXPERIMENTAL
Intervention: Standard FLS training platform with medical-grade consumables (S-FLS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-cost platform with training-grade products (LC-FLS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-cost platform consumables (LC-FLS)
Number of subjects: 39
Study: 25527758

Group type: EXPERIMENTAL
Intervention: Current use of multivitamins
Number of subjects: 37193

Group type: EXPERIMENTAL
Intervention: Updated multivitamin use during follow-up
Number of subjects: 37193